EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access

Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy

Longting Lin, Feifeng Liu, Tingyu Yi, Yueqi Zhu, Jianhong Yang, Yanxin Zhao, Feng Wang, Guangyu Xiang, Chen Chen, Yaping Xiao, Hao Shen, Luran Xu und 9 weitere

JAMA Network Open · 17.04.2025 · 8 (4) · e255308

DOI: 10.1001/jamanetworkopen.2025.5308 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 17.04.2025. Verfasst von Longting Lin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Shanghai East Hospital, Tongji University School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Tirofiban, Thrombectomy, Endovascular Procedures, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Tirofiban is a nonpeptide antagonist of the glycoprotein IIb/IIIa receptor that inhibits platelet aggregation selectively. Despite widespread use in acute ischemic stroke in conjunction with endovascular treatment, the role of tirofiban is uncertain.

Objective

To assess whether intravenous tirofiban initiated before endovascular thrombectomy improves thrombectomy outcomes by achieving first-pass recanalization without intracranial hemorrhagic risk. Design, Setting, and Participants This was a multicenter, prospective, open-label, blinded, end point phase 2 randomized clinical trial that enrolled patients from 7 Chinese hospital stroke centers between April 30, 2021, and July 16, 2023. Eligible patients were aged 18 to 85 years with large vessel occlusion (internal carotid artery or M1 or M2 segment of middle cerebral artery) and were considered for endovascular thrombectomy within 24 hours of ischemic stroke onset or last known well time. Patients with a history of atrial fibrillation or treated with intravenous thrombolysis were excluded.

Intervention

Patients were randomly assigned (1:1) to intravenous tirofiban (10 μg/kg bolus plus 0.1 μg/kg per minute infusion for 24 hours) or standard care before endovascular thrombectomy using a web-based, computer-generated randomization procedure. Main Outcomes and Measures The primary outcome was the proportion of patients achieving first-pass recanalization without symptomatic intracranial hemorrhage. First-pass recanalization was assessed by reviewers blinded to treatment allocation and predefined as successful recanalization of a targeted vessel after a single pass of thrombectomy. The primary outcome was analyzed by modified Poisson regression with robust error estimation, adjusting for time from onset or last known well time to randomization and vessel occlusion site.

Results

Among 200 patients randomized (median age, 66 years [IQR, 58-72 years]; 146 male [73%]), 102 were allocated to receive intravenous tirofiban, and 98 were allocated to receive standard care before endovascular thrombectomy. In the intention-to-treat analysis, 64 of 99 patients receiving tirofiban (65%) and 46 of 95 control patients (48%) achieved the primary outcome of first-pass recanalization without symptomatic intracranial hemorrhage (adjusted risk ratio, 1.34 [95% CI, 1.04-1.73]; P = .03). Incidence of symptomatic intracranial hemorrhage was 0% (0 of 101 patients) in the tirofiban group vs 6% (6 of 98 patients) in the control group (unadjusted risk difference, −0.06 [95% CI, −0.11 to −0.01]). Conclusions and Relevance In this randomized clinical trial of patients who had acute ischemic stroke with no history of atrial fibrillation and no prior intravenous thrombolysis, intravenous tirofiban administered before endovascular thrombectomy increased the likelihood of first-pass recanalization without symptomatic intracranial hemorrhage. These findings suggest that neurointerventionalists may consider this pre-procedure antiplatelet treatment to facilitate endovascular thrombectomy. Trial Registration ClinicalTrials.gov Identifier: NCT04851457

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirofibanThrombectomyEndovascular ProceduresPlatelet Aggregation InhibitorsIschemic StrokeStrokeHumansMaleFemaleMiddle AgedAgedProspective StudiesAged, 80 and overTreatment OutcomeAdultIntracranial Hemorrhages

Substanzen

TirofibanPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Shanghai East Hospital, Tongji University School of Medicine, Tongji University, Shanghai, China.
  • Sino-Australian Neurological Clinical Research Cooperation Centre, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
  • South Western Sydney Clinical Campuses, University of New South Wales and Ingham Institute for Applied Medical Research, Sydney, New South Wales Australia.
  • Department of Neurointervention, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou Municipal Hospital, Fujian, China.
  • Department of Radiology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Neurology, The First Affiliated Hospital of Ningbo University, Zhejiang, China.

Zitieren

APA

Lin, L., Liu, F., Yi, T., Zhu, Y., Yang, J., Zhao, Y., Wang, F., Xiang, G., Chen, C., Xiao, Y., Shen, H., Xu, L., Long, Y., Zhang, Y., Huang, Z., Chen, C., Churilov, L., Parsons, M. W., Chen, W., …, & OPTIMISTIC Investigators (2025). Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy. JAMA Network Open, 8(4), e255308. https://doi.org/10.1001/jamanetworkopen.2025.5308

Vancouver

Lin L, Liu F, Yi T, Zhu Y, Yang J, Zhao Y, et al. Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy. JAMA Network Open. 2025;8(4):e255308. doi:10.1001/jamanetworkopen.2025.5308

BibTeX
@article{Lin2025,
  author = {Lin, Longting and Liu, Feifeng and Yi, Tingyu and Zhu, Yueqi and Yang, Jianhong and Zhao, Yanxin and Wang, Feng and Xiang, Guangyu and Chen, Chen and Xiao, Yaping and Shen, Hao and Xu, Luran and Long, Yuming and Zhang, Yue and Huang, Zhengyu and Chen, Chushuang and Churilov, Leonid and Parsons, Mark W and Chen, Wenhuo and Li, Gang and OPTIMISTIC Investigators, OPTIMISTIC Investigators},
  title = {Tirofiban on First-Pass Recanalization in Acute Stroke Endovascular Thrombectomy},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {e255308},
  doi = {10.1001/jamanetworkopen.2025.5308}
}
Kostenlos starten →